Renal Cysts
Drug-induced complex renal cysts — the distinctive ALK-inhibitor lesion, classically crizotinib. Usually asymptomatic, dose/duration-related, and they tend to regress when the drug is stopped.
Where it strikes
Fine-tuning of Na, K, Mg, acid & water
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Management approach
Full framework →Usually asymptomatic and dose/duration-related; monitor, rarely act.
Drug-level levers
- Continue therapy in most cases; the cysts often regress when the drug is stopped.
- Hold and reassess only for complex cysts with concerning features or complications.
Pharmacologic toolkit
- No specific therapy — Surveillance imaging; intervention only for symptomatic or complicated cysts.
When to biopsy
Not routine; image characterization (and urology input) for complex or enlarging cysts to exclude malignancy.
Monitoring
- · Surveillance imaging as clinically indicated
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
Offending agents
Signature offenders
1Agents for which renal cysts is the defining renal lesion.